Disclaimer

Legal statement

The sole purpose of the www.nitecpharma.com website is to provide the public with general information about the activities of Nitec Pharma AG. By accessing this website you are deemed to take notice and to accept the contents of this Disclaimer.

No offer and no solicitation

The information provided on this Website does not constitute an offer of or solicitation for the purchase or disposal of, trading or any transaction in any securities of Nitec Pharma AG or affiliated companies. Investors must not rely on this information for investment decisions.

No warranty and no liability

While Nitec Pharma AG. is attempting to include accurate and up-to-date information, we make no representations or warranties, express or implied, as to the accuracy or completeness of the information provided on this website and disclaim any liability for the use of this site or any site linked to it. Nitec Pharma AG. may change this site (including this Legal Notice) at any time without notice but does not assume any responsibility to update it. All users agree that all access and use of this website is at their own risk.

Neither Nitec Pharma AG. nor any other party involved in creating, producing or delivering this website or on any website linked to from this site shall be liable in any manner whatsoever for any direct, incidental, consequential, indirect or punitive damages arising out of your access, use or inability to use this website or any website linked to from this site, or any errors or omissions in the content thereof.

Forward-looking information

This website may expressly or implicitly contain specific forward-looking statements, e.g. statements including, without limitation, statements containing the words “expects”, “believes”, “anticipates” - and similar expressions. Such information and forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Links

Links to third party pages are provided for convenience only. We do not express any opinion on the content of any third party websites and expressly disclaim any liability for all third party information and the use of it.

Copyright

The website of Nitec Pharma AG. and the information contained and referenced therein are for informational purposes only. Any reproduction, retransmission or other use of text or pictures is prohibited. Request for permission to reproduce any information contained on this website should be addressed to the webmaster of the website.
24/10/2007
Nitec Pharma to present 12-month efficacy and safety data for Lodotra at the annual meeting of the American College of Rheumatology in San Francisco
more
29/09/2008
Nitec Pharma AG secures funding of CHF 24M from TVM Capital and Deutsche Bank.
more
12/06/2008
Nitec to present Lodotra 12 month treatment data in Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR) in Paris.
more
22/01/2008
Nitec’s phase 3 results with Lodotra in RA published in current issue of The Lancet.
more
space
space
space